Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan.
Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Clin Lung Cancer. 2021 May;22(3):e431-e437. doi: 10.1016/j.cllc.2020.06.013. Epub 2020 Jun 19.
To evaluate long-term outcomes after sublobar resection for patients with clinical stage IA lung adenocarcinoma who met our proposed node-negative (N0) criteria, namely solid component size < 0.8 cm on high-resolution computed tomography (HRCT) or a maximum standardized uptake value (SUV) of < 1.5 on [F]-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT).
Between April 2006 and December 2010, a total of 347 patients with clinical stage IA lung adenocarcinoma underwent complete resection in two medical centers. Long-term outcomes of patients with disease that met the N0 criteria after sublobar resection were evaluated.
The disease of 201 patients (57.9%) met the N0 criteria. Meeting N0 criteria was significantly associated with low-grade adenocarcinoma subtype (P < .001) and absence of lymphatic invasion (P < .001), vascular invasion (P < .001), and pleural invasion (P < .001). One patient (0.5%) had lymph node metastasis. The median follow-up period was 86.1 months. There was a significant difference in the overall survival (OS) rates between patients with disease that met the N0 criteria (5-year OS, 93.9%; 10-year OS, 90.3%) and disease that did not (5-year OS, 81.5%; 10-year OS, 64.3%; P < .001). Among patients with disease that met the N0 criteria, there was no significant difference in the OS between those who underwent lobectomy (5-year OS, 94.3%; 10-year OS, 92.6%) and those who underwent sublobar resection (5-year OS, 93.8%; 10-year OS, 89.3%; P = .64).
Sublobar resection of clinical stage IA lung adenocarcinoma is feasible in selected patients with disease that meets the N0 criteria, with excellent long-term survival.
评估符合我们提出的淋巴结阴性(N0)标准的临床ⅠA 期肺腺癌患者行亚肺叶切除术后的长期结果,该标准为:高分辨率 CT(HRCT)上实性成分大小<0.8cm 或氟-18-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(FDG-PET/CT)上最大标准化摄取值(SUV)<1.5。
在 2006 年 4 月至 2010 年 12 月期间,两个医学中心共有 347 例临床ⅠA 期肺腺癌患者接受了完全切除术。评估亚肺叶切除术后符合 N0 标准的患者的疾病无复发生存情况。
201 例(57.9%)患者的疾病符合 N0 标准。符合 N0 标准与低级别腺癌亚型显著相关(P<0.001),且与无淋巴管浸润(P<0.001)、血管浸润(P<0.001)和胸膜浸润(P<0.001)显著相关。1 例(0.5%)患者发生淋巴结转移。中位随访时间为 86.1 个月。符合 N0 标准的患者的总生存(OS)率与不符合 N0 标准的患者有显著差异(5 年 OS,93.9%;10 年 OS,90.3%)(P<0.001)。在符合 N0 标准的患者中,行肺叶切除术的患者与行亚肺叶切除术的患者的 OS 无显著差异(5 年 OS,94.3%;10 年 OS,92.6%)(5 年 OS,93.8%;10 年 OS,89.3%)(P=0.64)。
在符合 N0 标准的患者中,可行亚肺叶切除术治疗临床ⅠA 期肺腺癌,长期生存效果极好。